Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Report Date: January 20, 2026
Event Date: January 15, 2026 (Agreement); January 20, 2026 (Closing)
Context: The Company entered into a Warrant Inducement Agreement with an institutional investor to facilitate the cash exercise of existing warrants at a reduced price, resulting in new capital raises and the issuance of new warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $4.6 million from the cash exercise of existing warrants.
- Use of Proceeds: General working capital and general corporate purposes.
- Transaction Fees:
- Cash fee to placement agent (H.C. Wainwright & Co., LLC): 7.0% of gross proceeds.
- Management fee to placement agent: 1.0% of gross proceeds.
- Placement Agent Warrants issued: 138,765 shares (representing 7.0% of underlying shares).
- Debt and Liquidity: The filing does not provide specific balance sheet data regarding total debt or current liquidity positions outside of the transaction proceeds.
Material Changes and Transaction Details
The Company executed a "Warrant Inducement Transaction" involving the following material changes:
- Exercise of Existing Warrants: The Holder exercised three existing warrants (January 2023, November 2023, and February 2024) covering a total of 1,982,356 shares. The exercise price was reduced from $3.83 and $5.05 to $2.34 per share to comply with Nasdaq listing rules.
- Issuance of New Warrants (Inducement Warrants): In consideration for the exercise, the Company issued two new warrants to the Holder:
- Series A: 5-year term, exercisable for up to 1,982,356 shares at $2.09/share. Includes a Black-Scholes put right.
- Series B: 24-month term, exercisable for up to 1,982,356 shares at $2.09/share. No Black-Scholes put right.
- Placement Agent Compensation: H.C. Wainwright & Co., LLC received cash fees and warrants (138,765 shares at $2.925/share exercise price).
Guidance, Outlook, and Risks
- Registration Obligations: The Company must file a resale registration statement by February 14, 2026, and aim for effectiveness by March 16, 2026 (or April 15, 2026 if under SEC review).
- Lock-Up Provisions: The Company is prohibited from issuing new equity or filing new registration statements (with limited exceptions) until February 19, 2026. A six-month prohibition on "variable rate transactions" applies following the effectiveness of the resale registration.
- Risks and Contingencies:
- Liquidated Damages: The agreement includes provisions for liquidated damages if Inducement Warrant Shares are not delivered upon future exercise.
- Anti-Dilution: Inducement Warrants contain stock-based anti-dilution protection.
- Cashless Exercise: If shares are not registered for resale at the time of exercise, a cashless exercise provision applies.
- Beneficial Ownership: Limitations exist but may be waived by the Holder with 61 days' notice.
- Management Commentary: No specific forward-looking guidance on clinical trials or revenue projections was provided in this filing; the focus is strictly on the capital transaction.
Investor Verification Checklist
- Verify the effective date of the Post-Effective Amendment to Form S-1 (File No. 333-278564) referenced for the resale of underlying shares.
- Confirm the exact net proceeds after deducting the 8.0% total cash fees (7.0% placement + 1.0% management) and any reimbursed expenses.
- Monitor the filing of the Resale Registration Statement by the February 14, 2026 deadline.
- Review the full text of the Warrant Inducement Agreement (Exhibit 10.1) for specific definitions of "Fundamental Transaction" and liquidated damages calculations.
- Assess the dilution impact of the 3,964,712 shares underlying the new Inducement Warrants and the 138,765 Placement Agent Warrants.